Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 11/20 | 0.52 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | GFER | P55789 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20411791 | 0.89 | DRD2 (0.47) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL14165710 | 0.88 | DRD2 (0.50) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL14075951 | 0.88 | DRD2 (0.50) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL16208607 | 0.88 | DRD2 (0.50) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL22252842 | 0.87 | DRD2 (0.49) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL31301242 | 0.83 | DRD2 (0.63) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL20411793 | 0.83 | DRD2 (0.50) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL25716981 | 0.82 | DRD2 (0.54) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL13202614 | 0.79 | DRD2 (0.59) | DRD2CACNA1HSIGMAR1TDP1CD274 | |
| SCHEMBL30418583 | 0.79 | USP2 (0.43) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200231551-A1 | COMPOSITIONS AND USES THEREOF | UNIVERSITY OF VIRGINIA | 2020-07-23 | — | — | US | disclosed |
| US-10570139-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BEIGENE SWITZERLAND GMBH (CH) | 2020-02-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200231551-A1 | COMPOSITIONS AND USES THEREOF | CYP11B2, NQO1, CYP11B1 | DRD2 4140/4885CACNA1H 4589/4885SIGMAR1 1168/4885 |
| US-10570139-B2 | Substituted pyrazolo[1,5-a]pyrimidines as Bruton's tyrosine kinase modulators | BTK, LCK, SYK | DRD2 4861/4885CACNA1H 3300/4885SIGMAR1 3653/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.